Access To Medicines

Today, one third of the world's population lacks access to essential medicines. In the poorest parts of Africa and Asia this figure rises to a half of the population.

MSF campaigns to challenge the high cost of existing medicines and the absence of treatment for many of the diseases affecting our patients.

Hover over the image below for an interactive guide to the MSF Access Campaign.

Today, one third of the world's population lacks access to essential medicines. In the poorest parts of Africa and Asia this figure rises to a half of the population.

Too often, MSF cannot treat patients because the medicines are too expensive, or they are no longer produced. Sometimes, the only drugs we have are highly toxic or ineffective and nobody is looking for a better cure.

As a medical humanitarian organisation, it is fundamentally unacceptable to MSF that access to essential medicines is increasingly difficult, particularly for the most common global infectious diseases.
 

MSF's Impact

In response to the need for better treatments, vaccines and diagnostic tests MSF set up its Access Campaign in 1999 to improve care for patients.

The aims of MSF Access Campaign are to:

  • Push for price cuts to medicines, vaccines and diagnostic tests by stimulating the production of more affordable generic products     
  • Act as a watchdog to ensure that the corporate interests don’t win out over public health needs     
  • Steer the direction of medical research toward urgently needed new drugs, vaccines and tests that don’t exist yet or are not tailored to the needs of people in developing countries     
  • Scope out, support and monitor new models to fund medical research that respond to medical rather than corporate needs and do not rely on charging sky high prices for the final product to pay for the research     

In 2003, MSF joined forces with six other organisations from around the world to establish the Drugs For Neglected Diseases Initiative (DNDi), with the aim of developing new drugs or new formulations of existing drugs for patients suffering from the most neglected communicable diseases.

DNDi seeks to address unmet needs by taking on projects that others are unable or unwilling to pursue.
 

MSF is well known for its humanitarian medical work, but it has also produced important research based on its field experience with vulnerable communities .

This website archives MSF's scientific articles and makes them available free, with full text and in an easily searchable format. MSF Field Research website.

MSF is also pushing for increased research into neglected diseases – such as tuberculosis, malaria, sleeping sickness and leishmaniasis – through increased funding, investing in research and development (R&D) capability in developing countries and supporting alternative models for R&D

Some treatments are no longer produced. MSF is calling on companies and governments to find solutions to bring unprofitable but medically necessary drugs back into production.

MSF is also supporting developing countries in codifying into law the "safeguards" that are allowed under international trade rules in order to protect access to medicines.

 
Picture of MSF staff in PPE
Vaccination

Creation of the Ebola vaccine stockpile, a positive step

Press Release 12 Jan 2021
 
Graphic with text "Our wishes for 2021"
Access To Medicines

Our Wishlist for 2021

Latest News 8 Jan 2021
 
MSF, Doctors Without Borders, Central African Republic, violence
Armed conflict

MSF provides care in post-election attacks in Bangassou, CAR

Press Release 4 Jan 2021
 
MSF, Doctors Without Borders, Mozambique, violence, crisis
Armed conflict

A crisis is unfolding in Mozambique

Latest News 27 Dec 2020
 
MSF, Doctors Without Borders, COVID-19, Spain,
Access to Healthcare

A year in pictures 2020

Latest News 22 Dec 2020
 
MSF, Docotrs Without Borders, Ethiopia, Tigray region conflict
Armed conflict

Psychological support for MSF staff on the border with Tigray, Ethiopia

Latest News 22 Dec 2020